United Therapeutics Corporation Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
United Therapeutics Corporation (UTHR) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.00 per share for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2014-02-25
- United Therapeutics Corporation income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2012-09-30 was $0.00, a 100.00% decline year-over-year.
- United Therapeutics Corporation income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2012-06-30 was $0.00.
- United Therapeutics Corporation income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2012-03-31 was $0.00.
- United Therapeutics Corporation income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2011-09-30 was $0.07.
- United Therapeutics Corporation income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2013 was $0.00.
- United Therapeutics Corporation income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- United Therapeutics Corporation income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2011 was $0.01.
- United Therapeutics Corporation income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2010 was -$0.09, a 1000.00% decline from fiscal 2009.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 | |||
| 2012-12-31 | $0.00 10-K · filed 2014-02-25 | |||
| 2012-09-30 | $0.00 10-Q · filed 2012-11-01 | $0.00 10-Q · filed 2012-11-01 | ||
| 2012-06-30 | $0.00 10-Q · filed 2012-07-26 | $0.00 10-Q · filed 2012-07-26 | ||
| 2012-03-31 | $0.00 10-Q · filed 2012-04-26 | |||
| 2011-12-31 | $0.01 10-K · filed 2014-02-25 | |||
| 2011-09-30 | $0.07 10-Q · filed 2012-11-01 | $0.01 10-Q · filed 2012-11-01 | ||
| 2011-06-30 | $0.00 10-Q · filed 2012-07-26 | -$0.05 10-Q · filed 2012-07-26 | ||
| 2011-03-31 | -$0.06 10-Q · filed 2012-04-26 | |||
| 2010-12-31 | -$0.09 10-K · filed 2013-02-26 | |||
| 2010-09-30 | -$0.01 10-Q · filed 2011-10-27 | -$0.01 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | -$0.01 10-Q · filed 2011-07-28 | -$0.01 10-Q · filed 2011-07-28 | ||
| 2009-12-31 | $0.01 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |